Cardiovascular Risk in General Practice in France: Cardiovascular Risk Week

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01308372
First received: February 18, 2011
Last updated: November 4, 2011
Last verified: November 2011

February 18, 2011
November 4, 2011
October 2011
October 2011   (final data collection date for primary outcome measure)
Evaluation of cardiovascular risk in general practice in France estimated by the SCORE scale [ Time Frame: 1 week ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01308372 on ClinicalTrials.gov Archive Site
  • Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 2008 scale D'Agostino [ Time Frame: 1 week ] [ Designated as safety issue: No ]
  • Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 1998 scale Wilson [ Time Frame: 1 week ] [ Designated as safety issue: No ]
  • Evaluation of arteries age evaluation by SCORE [ Time Frame: 1 week ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Cardiovascular Risk in General Practice in France: Cardiovascular Risk Week
Cardiovascular Risk in General Practice in France

The purpose of this study is to evaluate the proportion of patients which present a high cardiovascular risk estimated by the SCORE scale, in general practice consultations of the 7 French regions (Paris area, North-East, Paris basin, West, South-West, South- East, Mediterranean area)

MC MD

Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample

Primary care

Healthy
Not Provided
1
For this group of patients, the cardiovascular risk will be evaluated by several tools: the SCORE scale, the Framingham 2008 scale d'Agostino and the 1998 scale Wilson ;
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
9246
October 2011
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Without any personal history of coronary disease
  • Non treated with lipid-lowering agents
  • Lipid test = 1 year old
  • Presenting at least one cardiovascular risk
  • Visiting their General Practitioner

Exclusion Criteria:

Both
50 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01308372
NIS-CFR-XXX-2011/1
No
AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Eric BRUCKERT, Pr. Hôpital Pitié-Salpétrière - Service Endocrinologie-Métabolisme
Principal Investigator: Jean DALLONGEVILLE, Dr. Institut Pasteur de Lille - Unité d'Epidémiologie et de santé publique Inserm UMR 744
Principal Investigator: Jean FERRIERES, Pr. CHU Rangueil - Service de Cardiologie B - Toulouse
Principal Investigator: Serge KOWNATOR, Dr. Thionville -Société Française de Cardiologie
AstraZeneca
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP